Royalty Pharma Dirección

Dirección controles de criterios 3/4

El CEO de Royalty Pharma es Pablo Legorreta, nombrado en Jan 1996, tiene una permanencia de 28.83 años. posee directamente un 0.83% de las acciones de la empresa, con un valor de MX$2.59B. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 4.4 años, respectivamente.

Información clave

Pablo Legorreta

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	28.8yrs
Participación del CEO	0.8%
Permanencia media de la dirección	2.1yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Pablo Legorreta en comparación con los beneficios de Royalty Pharma?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	US$1b
Jun 30 2024	n/a	n/a	US$673m
Mar 31 2024	n/a	n/a	US$799m
Dec 31 2023	n/a	n/a	US$1b
Sep 30 2023	n/a	n/a	US$184m
Jun 30 2023	n/a	n/a	US$255m
Mar 31 2023	n/a	n/a	US$332m
Dec 31 2022	n/a	n/a	US$43m
Sep 30 2022	n/a	n/a	US$507m
Jun 30 2022	n/a	n/a	US$466m
Mar 31 2022	n/a	n/a	US$602m
Dec 31 2021	US$50m	US$8m	US$620m
Sep 30 2021	n/a	n/a	US$783m
Jun 30 2021	n/a	n/a	US$972m
Mar 31 2021	n/a	n/a	US$493m
Dec 31 2020	US$56m	n/a	US$495m
Sep 30 2020	n/a	n/a	US$2b
Jun 30 2020	n/a	n/a	US$2b
Mar 31 2020	n/a	n/a	US$2b
Dec 31 2019	US$29m	n/a	US$2b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Pablo es razonable en comparación con empresas de tamaño similar en el mercado MX.

Compensación vs. Ingresos: La compensación de Pablo ha sido consistente con los resultados de la empresa en el último año.

CEO

Pablo Legorreta (60 yo)

28.8yrs

Permanencia

Mr. Pablo Gerardo Legorreta serves as Chairman of the Board at ProKidney Corp. He is a Co-Founder & Director of Sequel Med Tech, LLC. He serves as the Chief Executive Officer and Co-Founder at RP Managemen...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Pablo Legorreta	Founder	28.8yrs	sin datos	0.83% MX$ 2.6b
Terrance Coyne	Executive VP & CFO	no data	US$4.56m	0.19% MX$ 593.2m
George Lloyd	Executive VP of Investments & Chief Legal Officer	2.1yrs	US$4.56m	0.24% MX$ 760.1m
Christopher Hite	Vice Chairman & Executive VP	4.6yrs	US$4.56m	0.083% MX$ 261.2m
Marshall Urist	Executive Vice President of Research & Investments	3.9yrs	US$4.56m	0.015% MX$ 46.4m
Arthur McGivern	Executive Vice President of Investments & General Counsel	2.1yrs	sin datos	sin datos
Ashwin Pai	Executive Vice President of Investments	1.6yrs	sin datos	sin datos
Kristin Stafford	Senior VP & Chief Accounting Officer	no data	sin datos	sin datos
Eric Schneider	Senior VP & Chief Technology Officer	1.2yrs	sin datos	sin datos
James Reddoch	Executive VP of Investments & Chief Scientific Officer	3.9yrs	US$3.40m	sin datos
George Grofik	Senior VP and Head of Investor Relations & Communications	no data	sin datos	sin datos
Molly Sawaya	Executive VP & Head of Human Capital	less than a year	sin datos	sin datos

2.1yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de RPRX N se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Pablo Legorreta	Founder	28.8yrs	sin datos	0.83% MX$ 2.6b
David Hodgson	Independent Director	2.4yrs	US$389.77k	0.0037% MX$ 11.6m
Ted Love	Independent Director	4.3yrs	US$389.77k	0.0083% MX$ 26.1m
Errol De Souza	Independent Director	4.4yrs	US$389.77k	0.015% MX$ 45.5m
Henry Fernandez	Lead Independent Director	4.3yrs	US$389.77k	0.023% MX$ 72.6m
Gregory Norden	Independent Director	4.4yrs	US$389.77k	0.015% MX$ 45.5m
Bonnie Bassler	Independent Director	4.4yrs	US$389.77k	0.011% MX$ 35.7m
Catherine Engelbert	Independent Director	4.4yrs	US$389.77k	0.0077% MX$ 24.1m

4.4yrs

Permanencia media

65.5yo

Promedio de edad

Junta con experiencia: La junta directiva de RPRX N se considera experimentada (4.4 años de antigüedad promedio).

Royalty Pharma Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Insufficient new directors

Insufficient new directors

Insufficient new directors

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Recent updates

New minor risk - Earnings quality

Upcoming dividend of US$0.21 per share

Third quarter 2024 earnings released: EPS: US$0.92 (vs US$0.16 in 3Q 2023)

Second quarter dividend of US$0.21 announced

Royalty Pharma plc to Report Q3, 2024 Results on Nov 06, 2024

Insufficient new directors

Royalty Pharma Declares Fourth Quarter 2024 Dividend, Payable on December 10, 2024

Insufficient new directors

Second quarter 2024 earnings released: EPS: US$0.23 (vs US$0.51 in 2Q 2023)

Insufficient new directors

Royalty Pharma plc Appoints Molly Sawaya as Executive Vice President, Head of Human Capital

Royalty Pharma plc to Report Q2, 2024 Results on Aug 08, 2024

Royalty Pharma plc Declares Dividend for the Third Quarter of 2024, Payable on September 13, 2024

Royalty Pharma plc Announces the Resignation of Rory Balfour Riggs as Director

Royalty Pharma plc Announces Resignation of Mario Germano Giuliani as Director

Insufficient new directors

Royalty Pharma plc, Annual General Meeting, Jun 06, 2024

Royalty Pharma plc Declares Dividend for the Second Quarter of 2024, Payable on June 14, 2024

Insufficient new directors

Royalty Pharma plc to Report Q1, 2024 Results on May 09, 2024

Insufficient new directors

Royalty Pharma plc to Report Q4, 2023 Results on Feb 15, 2024

Third quarter dividend of US$0.21 announced

Insufficient new directors

Royalty Pharma plc Declares Dividend for the First Quarter of 2024, Payable on March 15, 2024

Director recently sold Mex$120m worth of stock

Director recently sold Mex$336m worth of stock

Insufficient new directors

Royalty Pharma Appoints Eric Schneider as Chief Technology Officer

Insufficient new directors

Royalty Pharma plc Declares Dividend on Class A Ordinary Shares for the Third Quarter of 2023, Payable on September 15, 2023

Executive VP & CFO recently sold Mex$39m worth of stock

Founder recently bought Mex$66m worth of stock

Royalty Pharma plc to Report Q2, 2023 Results on Aug 08, 2023

Director recently sold Mex$92m worth of stock

High number of new and inexperienced directors

Upcoming dividend of US$0.20 per share at 2.1% yield

High number of new and inexperienced directors

Royalty Pharma plc to Report Q4, 2022 Results on Feb 15, 2023

Royalty Pharma Declares First Quarter 2023 Dividend, Payable on March 15, 2023

Royalty Pharma Announces Expansion of Senior Leadership Team

Royalty Pharma Declares Fourth Quarter 2022 Dividend, Payable on December 15, 2022

Royalty Pharma plc Announces Executive Changes

Royalty Pharma plc to Report Q3, 2022 Results on Nov 08, 2022

Director recently sold Mex$438k worth of stock

High number of new and inexperienced directors

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Royalty Pharma plc Declares Third Quarter 2022 Dividend, to Be Paid on September 15, 2022

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

High number of new and inexperienced directors

Royalty Pharma plc to Report Q2, 2022 Results on Aug 04, 2022

Royalty Pharma plc Announces Directorate Change

Insider recently sold Mex$81m worth of stock

Insider recently sold Mex$79m worth of stock

Insider recently sold Mex$80m worth of stock

High number of new and inexperienced directors

Director recently sold Mex$118m worth of stock

Upcoming dividend of US$0.19 per share

High number of new and inexperienced directors

Análisis de compensación del CEO

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad